Pooled data from dozens of studies place the overall five-year survival rate for people living with heart failure at roughly 57 percent, and the ten-year survival rate at about 35 percent.1European Journal of Heart Failure. Survival of Patients with Chronic Heart Failure in the Community: A Systematic Review and Meta-Analysis Those numbers, however, are averages across a wide range of ages, disease severities, and treatment regimens. Individual prognosis swings dramatically depending on how well the heart pumps, what caused the failure, which medications a person takes, and a handful of other factors that deserve a closer look.
How Survival Has Changed Over the Decades
Heart failure used to carry a grimmer outlook than it does today. Data from Framingham, Massachusetts, tracking patients from the 1950s through the 1990s, showed five-year mortality in men falling from about 70 percent in the earliest decades to 59 percent by the 1990s. Women saw an even steeper improvement, from 57 percent five-year mortality down to 45 percent. Overall, survival improved by roughly 12 percent per decade.2PubMed. Long-term trends in the incidence of and survival with heart failure That trend continued into the 2000s. A large UK population study found that one-year survival climbed from about 74 percent in 2000 to 81 percent by 2016, and five-year survival rose from 41 percent to 48 percent over a similar window.3PubMed. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study
The gains have not been evenly distributed, though. A study of more than 86,000 individuals found that while cardiovascular death after a new heart failure diagnosis dropped meaningfully between 2002 and 2013, deaths from non-cardiovascular causes actually rose over the same period. One-year mortality stayed stubbornly high at around 32 percent, declining only modestly.4JAMA Cardiology. Temporal Trends and Patterns in Mortality After Incident Heart Failure: A Longitudinal Analysis of 86 000 Individuals In other words, better heart drugs are keeping more people alive from the cardiac side, but people with heart failure also tend to be older and carry other serious conditions. The net effect is that overall mortality has improved, but not as fast as the cardiac-specific numbers might suggest.
Ejection Fraction and Heart Failure Type
Doctors classify heart failure partly by how well the left ventricle squeezes blood out with each beat, a measurement called ejection fraction. Heart failure with a reduced ejection fraction (HFrEF) means the heart muscle has weakened and cannot pump forcefully enough. Heart failure with a preserved ejection fraction (HFpEF) means the heart squeezes adequately but is too stiff to fill properly between beats. You might expect the weak-pump version to carry a worse prognosis, and in many studies it does. A multi-ethnic international cohort found that, after accounting for age, sex, and other risk factors, patients with HFpEF had a roughly 38 percent lower risk of death over two years compared with those who had HFrEF.5European Heart Journal. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study
That said, the gap is not as large as many assume. One population-based study followed patients for five years and found virtually identical survival rates: 43 percent for those with preserved ejection fraction versus 46 percent for those with reduced ejection fraction.6PubMed. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study The likely explanation is that HFpEF patients tend to be older and carry more conditions such as obesity, diabetes, and kidney disease, which erode the survival advantage their stronger pump might otherwise provide. For you as a patient, ejection fraction matters, but it is only one piece of the puzzle.
How Symptom Severity Shapes Prognosis
The New York Heart Association (NYHA) classification system groups heart failure patients into four classes based on how limited they feel during daily activity: Class I means no real limitations, while Class IV means symptoms even at rest. These classes track powerfully with mortality. In patients with preserved ejection fraction, all-cause death rates across classes I through IV were roughly 15 percent, 21 percent, 36 percent, and 58 percent, respectively. Compared with Class I, Class IV patients faced more than eight times the mortality risk.7American Heart Journal. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function
Even within the milder classes, the distinction between Class II and Class III is where prognosis separates most sharply. An analysis of the PARADIGM-HF trial found that moving from Class II to Class III raised the risk of cardiovascular death or heart failure hospitalization by about 49 percent, a bigger jump than the move from Class I to II.8JAMA Cardiology. Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure The NYHA class is a subjective measure, though, and a blood test called NT-proBNP can refine the picture. That same analysis showed that Class I patients with high NT-proBNP levels actually did worse than Class II or even Class III patients with lower levels. Symptom severity matters, but so does what the blood markers are saying underneath.
Mortality rates at 20 months varied substantially depending on which trial the data came from: Class II patients ranged from 7 percent to 15 percent, and Class III patients from 12 percent to 26 percent.9PubMed Central. Clinical Implications of the New York Heart Association Classification That variation reflects differences in background treatments, patient demographics, and the era the trial was run in. The takeaway: NYHA class gives a useful direction-of-travel estimate, but the absolute numbers shift with context.
Age, Sex, and Personal Demographics
Age is probably the single strongest predictor of how long someone with heart failure will live. In a hospital-based cohort, the average remaining lifespan ranged from about 19.5 years for low-risk women under 50 all the way down to 2.9 years for high-risk men over 80. The overall average was 5.5 years.10PubMed Central. The average lifespan of patients discharged from hospital with heart failure That enormous range underscores why asking “what is the life expectancy” without specifying age is almost meaningless.
Sex also plays a role. Women with heart failure consistently outlive men. In large clinical trials of HFrEF, women had about a 32 percent lower risk of dying and a 20 percent lower risk of being hospitalized for heart failure compared with men.11PubMed. Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women A separate study estimated that men with heart failure lose about 2.4 years of life expectancy relative to the general population, while women lose about 1.6 years. Among women without major comorbidities, the loss of life expectancy was small enough to be statistically indistinguishable from zero.12PubMed. Association of heart failure and its comorbidities with loss of life expectancy The reasons are not fully settled, but women are more likely to develop the preserved-ejection-fraction type and tend to present at older ages, which paradoxically may reflect a slower disease progression earlier in life.
What Caused the Heart Failure
Not all heart failure is created equal when it comes to outlook. Heart failure caused by coronary artery disease (sometimes called ischemic cardiomyopathy) generally carries a worse prognosis than heart failure triggered by other causes such as viral infections, valve problems, or long-standing high blood pressure.13PubMed. Ischemic versus non-ischemic heart failure: should the etiology be determined? Both all-cause death and sudden cardiac death are higher in the ischemic group.14Indian Heart Journal. Clinical characteristics and long-term prognosis of ischemic and non-ischemic cardiomyopathy The reason is partly that scarred heart tissue from prior heart attacks creates electrical instability that raises the risk of fatal arrhythmias, and partly that the coronary disease itself often continues to progress.
Comorbidities That Shorten Life Expectancy
Heart failure rarely travels alone. Diabetes, kidney disease, chronic lung disease, and anemia all compound the problem. A Swiss study estimated that heart failure patients with type 2 diabetes lived about 5.4 months less on average than those without it. Kidney disease shaved off about 9 months. Having both diabetes and kidney disease together cost roughly 14.8 months of life expectancy compared with patients who had neither.15PubMed Central. Impact of type 2 diabetes on life expectancy and role of kidney disease among inpatients with heart failure in Switzerland These losses stack on top of the heart failure itself, which is why managing blood sugar and preserving kidney function are such high priorities in treatment plans.
Cognitive impairment is another often-overlooked complication. Problems with memory and executive function are common in heart failure, and they undermine a person’s ability to manage medications, recognize worsening symptoms, and follow fluid and diet restrictions. Patients with severe cognitive decline face higher readmission rates and worse short- and long-term survival.16PubMed Central. Cognitive Impairment in Heart Failure—A Review If you are caring for someone with heart failure who seems increasingly forgetful or confused, flagging that for their care team can make a real difference.
How Modern Medications Change the Outlook
The biggest reason survival has improved over the past few decades is better drug therapy. Guideline-directed medical therapy (GDMT) for HFrEF typically combines several classes of medication that collectively reduce the strain on the heart, block harmful hormonal signals, and reduce fluid buildup. Patients not receiving GDMT face roughly 29 to 37 percent higher mortality than those on a full regimen.17PubMed Central. Mortality and guideline‐directed medical therapy in real‐world heart failure patients with reduced ejection fraction The benefit holds even for older patients: a recent meta-analysis found that older adults with weakened heart function on GDMT had about a 31 percent lower risk of dying compared with those not on these treatments.18PubMed. Survival benefit of guideline-directed medical therapy in older patients with heart failure: a systematic review and meta-analysis
A striking recent study compared heart failure patients on full GDMT with patients who had various cancers. Those on the most modern combination, which includes a class of drug called an angiotensin receptor-neprilysin inhibitor, had significantly better survival than the cancer patients. Those not on GDMT actually had worse survival than the cancer cohort.19PubMed Central. Comparative Mortality in Heart Failure on Guideline-Directed Medical Therapy Versus Malignant Cancer That comparison reframes the stakes: heart failure on proper treatment is a manageable chronic illness, while heart failure without proper treatment can be as deadly as cancer.
One of the more exciting additions to the toolkit in recent years has been SGLT2 inhibitors, a class originally developed for diabetes. A meta-analysis found that SGLT2 inhibitors cut the combined risk of heart failure hospitalization and cardiovascular death by about 24 percent in heart failure patients, and the benefit held regardless of whether the patient had diabetes, kidney disease, or a reduced or preserved ejection fraction.20PubMed. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations These drugs have now become a cornerstone of heart failure treatment across the board.21PubMed Central. The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit
What Happens After a Heart Failure Hospitalization
Being admitted to the hospital for worsening heart failure is itself a turning point. Data from Australia and New Zealand show that the death rate is highest in the first three months after a heart failure hospitalization. Only about 70 percent of patients survive the first year, roughly 48 percent make it to three years, and about 34 percent are alive at five years.22European Journal of Heart Failure. Long-Term Survival and Life Expectancy Following an Acute Heart Failure Hospitalization in Australia and New Zealand These numbers are noticeably worse than the community-based averages cited earlier, because people sick enough to be hospitalized represent a more advanced slice of the disease. Each subsequent hospitalization tends to further worsen the trajectory, making aggressive prevention of readmission a top clinical priority.
Surgical Options for Advanced Heart Failure
When medications are no longer enough, surgical interventions come into the picture. Heart transplantation remains the gold standard for end-stage disease. The median survival after a heart transplant is around 10.7 years, and one center reported 20-year actuarial survival of about 56 percent.23Best Practice & Research Clinical Anaesthesiology. Long-term outcomes and management of the heart transplant recipient 24The Annals of Thoracic Surgery. Surviving 20 Years After Heart Transplantation: A Success Story Donor hearts are scarce, though, and many patients are too old or too sick to qualify.
For those who cannot get a transplant, a left ventricular assist device (LVAD) is an increasingly viable option. These are small mechanical pumps implanted in the chest that help the weakened heart push blood forward. Modern magnetically levitated LVADs have shown five-year mortality of about 38 percent overall, and in patients without additional risk factors that figure drops to roughly 23 percent.25PubMed. Predictors of 5-Year Mortality in Patients Managed With a Magnetically Levitated Left Ventricular Assist Device Some patients remain on LVAD support for many years: one registry reported seven-year survival of 51 percent among patients bridging to transplant.26PubMed. Long-Term Survival of Patients With Advanced Heart Failure Receiving an Left Ventricular Assist Device Intended as a Bridge to Transplantation Compare that with patients too sick for a transplant who instead rely on intravenous heart-stimulating drugs alone: their average survival is estimated at just 9.4 months.27PubMed. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure LVADs come with their own complications, including stroke risk and infection at the drive-line site, but for the right patient the survival gains are substantial.
Exercise and Cardiac Rehabilitation
It might seem counterintuitive to exercise a failing heart, but structured cardiac rehabilitation programs consistently show benefits. A large observational study found that patients who participated in cardiac rehab had about a 33 percent lower risk of dying from any cause and a lower risk of being rehospitalized for heart failure.28PubMed. Multidisciplinary Cardiac Rehabilitation and Long-Term Prognosis in Patients With Heart Failure A Cochrane review of randomized trials was more cautious about short-term mortality, finding no clear reduction within the first year, but it did find that exercise-based rehab cut overall hospital admissions by about 31 percent and meaningfully improved quality of life.29Cochrane Database of Systematic Reviews. Exercise-based cardiac rehabilitation for heart failure Expert panels now consider cardiac rehab safe and beneficial across heart failure types, with improvements in exercise capacity, functional independence, and symptom burden.30PubMed. Cardiac Rehabilitation for Patients With Heart Failure: JACC Expert Panel
The disconnect between the observational and trial data on mortality likely reflects that randomized trials tend to be short (under a year), while the survival benefits of staying active accumulate over longer periods. Either way, people with heart failure who are able to exercise in a supervised setting tend to feel better, stay out of the hospital more, and maintain greater independence.
Predicting Your Individual Risk
Population averages are useful context, but what most people really want to know is how long they specifically might live. Several validated risk calculators exist that combine factors like age, ejection fraction, NYHA class, kidney function, blood pressure, body weight, diabetes status, and whether the patient is on key medications. One widely used model, the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score, was built from data on nearly 40,000 patients across 30 studies and identified 13 independent predictors of mortality. It stratifies patients into groups with three-year death rates ranging from about 10 percent in the lowest-risk group to 70 percent in the highest-risk group.31European Heart Journal. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies
Another tool, the Barcelona Bio-Heart Failure calculator, adds biomarker values to the mix and achieved a discrimination statistic of 0.79, meaning it correctly ranked patients by risk about 79 percent of the time.32PLOS ONE. Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator) Blood markers like BNP and NT-proBNP, which rise when the heart is under strain, consistently improve prediction accuracy. A meta-analysis found that each moderate rise in BNP was independently linked to about a 14 percent increase in the risk of dying.33PubMed. Prognostic value of natriuretic peptides in heart failure: systematic review and meta-analysis A systematic review confirmed that adding natriuretic peptide values to prediction models consistently improved their performance, though formal testing of the size of that improvement has been limited.34PubMed Central. Natriuretic peptides testing and survival prediction models for chronic heart failure
These calculators are not crystal balls. They estimate the likelihood of survival for a group of people who look statistically similar to you, not a personal countdown. But they can help you and your doctor have a more grounded conversation about goals of care, treatment intensity, and advance planning.
Remote Monitoring and Implanted Sensors
One emerging approach to keeping heart failure patients out of the hospital involves implanted sensors that track pressure inside the lungs. The CardioMEMS device, a small wireless sensor placed in the pulmonary artery during a catheter procedure, lets doctors monitor fluid buildup remotely and adjust medications before symptoms spiral into a full hospitalization.35PubMed Central. Remote pulmonary artery pressure‐guided management of patients with heart failure A meta-analysis of trials testing this approach found that it cut heart-failure-related hospitalizations by about 28 percent, though it did not show a clear effect on overall survival.36Scientific Reports. Effectiveness of remote pulmonary artery pressure estimating in heart failure: systematic review and meta-analysis Since hospitalizations are themselves associated with a steeper decline, reducing them may yield longer-term survival benefits that shorter trials have not had time to capture.
Palliative Care Alongside Active Treatment
Palliative care and hospice are not the same thing, and this is a common misconception that keeps heart failure patients from getting help they could use years before end of life. Palliative care focuses on controlling symptoms, improving communication with clinicians, and supporting caregivers, and it can be delivered alongside full disease-modifying treatment. A systematic review of randomized trials found that palliative care interventions roughly halved hospitalizations in advanced heart failure patients without any clear negative effect on survival.37European Journal of Heart Failure. The Impact of Palliative Care on Clinical and Patient-Centred Outcomes in Patients with Advanced Heart Failure Quality of life improved modestly, and caregiver satisfaction and anxiety were better in the palliative care groups.38PubMed. Palliative Care Across the Spectrum of Heart Failure
The reluctance to bring up palliative care stems partly from its association with dying and partly from the unpredictable trajectory of heart failure itself. Unlike many cancers, where decline tends to follow a roughly predictable path, heart failure often involves repeated episodes of sharp worsening followed by partial recovery, making it hard to know when someone is in their final months. That unpredictability is actually an argument for earlier palliative involvement, not later.
Socioeconomic and Racial Disparities
Where you live and what resources you have access to meaningfully affect your survival with heart failure. In the ARIC study, low income was linked to a 52 percent higher risk of dying and a 45 percent higher risk of hospital readmission. Low education carried similar penalties.39PubMed Central. Impact of Socioeconomic Status on Mortality and Readmission in Patients With Heart Failure With Reduced Ejection Fraction Living in a highly deprived neighborhood independently raised readmission risk as well, even after accounting for personal income and education.
Racial patterns are more complex. A large analysis of in-hospital mortality found that Black and Hispanic patients hospitalized for heart failure actually had lower in-hospital death rates than White patients. However, socioeconomic status modulated that picture: racial and ethnic differences in outcomes were more pronounced among patients in low-income groups.40Journal of Cardiac Failure. The Association Between Socioeconomic Status, Sex, Race / Ethnicity and In-Hospital Mortality Among Patients Hospitalized for Heart Failure The reasons behind these patterns involve a tangle of age at diagnosis, disease type, access to specialists, insurance coverage, and follow-up care. What is clear is that two people with the same ejection fraction and the same NYHA class can face very different real-world prognoses depending on the socioeconomic cards they were dealt.